{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:13:29Z","timestamp":1793873609759,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clinthera.2022.09.012","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T06:00:39Z","timestamp":1666936839000},"page":"1520-1533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Zhi-Yuan","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-9310","authenticated-orcid":false,"given":"Jian-Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.09.012_bib0001","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1080\/14656566.2021.1970136","article-title":"Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update","volume":"16","author":"Pedersen-Bjergaard","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0002","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2146\/ajhp150174","article-title":"Insulin glargine 300 units\/mL: A new basal insulin product for diabetes mellitus","volume":"6","author":"Clements","year":"2016","journal-title":"Am J Health Syst Pharm"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2022.09.012_bib0003","first-page":"S1","article-title":"Introduction: Standards of Medical Care in Diabetes\u20142018","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP161682.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm\u20142017 executive summary","volume":"2","author":"Garber","year":"2017","journal-title":"Endocr Pract"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","article-title":"A review of the pharmacological properties of insulin degludec and their clinical relevance","volume":"9","author":"Haahr","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0006","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1007\/s11095-012-0739-z","article-title":"Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin","volume":"8","author":"Jonassen","year":"2012","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0007","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/14656566.2017.1400011","article-title":"Comparison between insulin degludec\/liraglutide treatment and insulin glargine\/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis","volume":"17","author":"Cai","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0008","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00592-018-1107-1","article-title":"Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"5","author":"Zhang","year":"2018","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"1","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0011","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"7414","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0012","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2337\/dc10-1925","article-title":"Insulin degludec in type 1 diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine","volume":"3","author":"Birkeland","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0013","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/dom.12573","article-title":"Comparison of insulin degludec with insulin detemir in type 1 diabetes: A 1-year treat-to-target trial","volume":"1","author":"Davies","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0014","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/dom.12298","article-title":"Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: A 26-week randomized, open-label, treat-to-target non-inferiority trial","volume":"10","author":"Davies","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0015","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"9825","author":"Garber","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0016","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.2337\/dc12-2329","volume":"9","author":"Gough","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0017","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(12)60204-9","article-title":"Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"9825","author":"Heller","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/dom.12411","article-title":"Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy","volume":"2","author":"Hollander","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0019","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.2040-1124.2012.00240.x","article-title":"Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial","volume":"1","author":"Iwamoto","year":"2013","journal-title":"J Diabet Invest"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2017.7115","article-title":"Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes the SWITCH 1 randomized clinical trial","volume":"1","author":"Lane","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0021","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type 2 diabetes","volume":"8","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0022","first-page":"660","article-title":"[The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial]","volume":"9","author":"Mu","year":"2017","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/jdi.12102","article-title":"Insulin degludec compared with insulin glargine in insulin-na\u00efve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial","volume":"6","author":"Onishi","year":"2013","journal-title":"J Diabetes Invest"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0024","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s13340-016-0267-x","article-title":"A comparison of IDeg","volume":"4","author":"Ono","year":"2016","journal-title":"Diabetol Int"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40268-016-0134-z","article-title":"A multinational, randomized, open-label, treat-to-target trial comparing insulin degludec and insulin glargine in insulin-na\u00efve patients with type 2 diabetes mellitus","volume":"2","author":"Pan","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0026","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00125-019-05080-9","article-title":"Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: The randomised, head-to-head CONCLUDE trial","volume":"4","author":"Philis-Tsimikas","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0027","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/dme.12303","article-title":"Comparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: A 2-year randomized, treat-to-target trial","volume":"11","author":"Rodbard","year":"2013","journal-title":"Diabetic Med"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0028","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2337\/dc18-0559","article-title":"More similarities than differences testing insulin glargine 300 units\/mL versus insulin degludec 100 units\/mL in insulin-naive type 2 diabetes: The randomized head-to-head BRIGHT trial","volume":"10","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0029","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/pedi.12263","article-title":"Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes","volume":"3","author":"Thalange","year":"2015","journal-title":"Pediatric Diabetes"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.2017.7117","article-title":"Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes the SWITCH 2 randomized clinical trial","volume":"1","author":"Wysham","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0031","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)","volume":"12","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0032","article-title":"Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials","author":"Liu","year":"2018","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.clinthera.2022.09.012_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:49Z","timestamp":1758963469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822003447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0149291822003447"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.09.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}